Highland Peak Capital LLC Has $6.94 Million Stock Position in Grifols, S.A. (NASDAQ:GRFS)

Key Points

• Highland Peak Capital LLC increased its stake in Grifols, S.A. by 24.1%, now owning approximately 5.1% of the company's stock valued at $6.9 million, making it their 7th largest holding.
• Recent analyst coverage includes a downgrade by Deutsche Bank to a "hold" rating, while Wall Street Zen upgraded Grifols to a "strong-buy," with a consensus price target set at $10.30.
• Grifols is set to pay a dividend of $0.1404 per share on August 20th, with an ex-dividend date on August 12th.

Highland Peak Capital LLC grew its stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 24.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 975,835 shares of the biotechnology company's stock after buying an additional 189,625 shares during the quarter. Grifols accounts for about 5.1% of Highland Peak Capital LLC's portfolio, making the stock its 7th largest holding. Highland Peak Capital LLC owned about 0.14% of Grifols worth $6,938,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc purchased a new stake in shares of Grifols in the first quarter valued at about $28,000. Tower Research Capital LLC TRC grew its position in Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 6,335 shares in the last quarter. First Trust Advisors LP acquired a new stake in Grifols during the 4th quarter worth approximately $75,000. Ballentine Partners LLC purchased a new position in shares of Grifols in the 1st quarter valued at about $77,000. Finally, Principal Street Partners LLC purchased a new stake in shares of Grifols in the 4th quarter valued at approximately $84,000.

Grifols Stock Up 0.1%

Shares of GRFS stock traded up $0.01 during trading hours on Friday, reaching $10.66. The company had a trading volume of 751,594 shares, compared to its average volume of 1,300,659. The stock's fifty day simple moving average is $9.43 and its 200 day simple moving average is $8.15. Grifols, S.A. has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.95 and a current ratio of 2.64. The company has a market capitalization of $7.33 billion, a P/E ratio of 9.11, a price-to-earnings-growth ratio of 0.36 and a beta of 0.56.

Grifols Dividend Announcement

The company also recently disclosed a -- dividend, which will be paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th will be issued a $0.1404 dividend. The ex-dividend date of this dividend is Tuesday, August 12th.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GRFS. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Finally, Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $10.30.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.